USP44 Promotes the Tumorigenesis of Prostate Cancer Cells through EZH2 Protein Stabilization

被引:41
作者
Park, Jae Min [1 ]
Lee, Jae Eun [1 ]
Park, Chan Mi [1 ]
Kim, Jung Hwa [1 ]
机构
[1] Inha Univ, Dept Biol Sci, Incheon 22212, South Korea
基金
新加坡国家研究基金会;
关键词
EZH2; prostate cancer cells; protein stability; USP44; TUMOR-SUPPRESSOR; GENE-EXPRESSION; HISTONE H3; E-CADHERIN; LYSINE; 27; POLYCOMB; UBIQUITINATION; REPRESSION; COMPLEX; TARGET;
D O I
10.14348/molcells.2018.0329
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ubiquitin-specific protease 44 (USP44) has been implicated in tumor progression and metastasis across various tumors. However, the function of USP44 in prostate cancers and regulatory mechanism of histone-modifying enzymes by USP44 in tumors is not well-understood. Here, we found that enhancer of zeste homolog 2 (EZH2), a histone H3 lysine 27 methyltransferase, is regulated by USP44. We showed that EZH2 is a novel target of USP44 and that the protein stability of EZH2 is upregulated by USP44-mediated deubiquitination. In USP44 knockdown prostate cancer cells, the EZH2 protein level and its gene silencing activity were decreased. Furthermore, USP44 knockdown inhibited the tumorigenic characteristics and cancer stem cell-like behaviors of prostate cancer cells. Inhibition of tumorigenesis caused by USP44 knockdown was recovered by ectopic introduction of EZH2. Additionally, USP44 regulates the protein stability of oncogenic EZH2 mutants. Taken together, our results suggest that USP44 promotes the tumorigenesis of prostate cancer cells partly by stabilizing EZH2 and that USP44 is a viable therapeutic target for treating EZH2-dependent cancers.
引用
收藏
页码:17 / 27
页数:11
相关论文
共 39 条
  • [11] Targeting EZH2 in cancer
    Kim, Kimberly H.
    Roberts, Charles W. M.
    [J]. NATURE MEDICINE, 2016, 22 (02) : 128 - 134
  • [12] SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
    Kim, Kimberly H.
    Kim, Woojin
    Howard, Thomas P.
    Vazquez, Francisca
    Tsherniak, Aviad
    Wu, Jennifer N.
    Wang, Weishan
    Haswell, Jeffrey R.
    Walensky, Loren D.
    Hahn, William C.
    Orkin, Stuart H.
    Roberts, Charles W. M.
    [J]. NATURE MEDICINE, 2015, 21 (12) : 1491 - +
  • [13] USP44 Is an Integral Component of N-CoR that Contributes to Gene Repression by Deubiquitinating Histone H2B
    Lan, Xianjiang
    Atanassov, Boyko S.
    Li, Wenqian
    Zhang, Ying
    Florens, Laurence
    Mohan, Ryan D.
    Galardy, Paul J.
    Washburn, Michael P.
    Workman, Jerry L.
    Dent, Sharon Y. R.
    [J]. CELL REPORTS, 2016, 17 (09): : 2382 - 2393
  • [14] The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer
    Le, Hanbo
    Zeng, Fang
    Xu, Liyun
    Liu, Xiaoguang
    Huang, Yanyan
    [J]. MOLECULAR MEDICINE REPORTS, 2013, 8 (05) : 1511 - 1518
  • [15] Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers
    Lee, Shuet Theng
    Li, Zhimei
    Wu, Zhenlong
    Aau, Meiyee
    Guan, Peiyong
    Karuturi, R. K. Murthy
    Liou, Yih Cherng
    Yu, Qiang
    [J]. MOLECULAR CELL, 2011, 43 (05) : 798 - 810
  • [16] SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer
    Lu, W.
    Liu, S.
    Li, B.
    Xie, Y.
    Izban, M. G.
    Ballard, B. R.
    Sathyanarayana, S. A.
    Adunyah, S. E.
    Matusik, R. J.
    Chen, Z.
    [J]. ONCOGENE, 2017, 36 (10) : 1364 - 1373
  • [17] A687V EZH2 is a gain-of-function mutation found in lymphoma patients
    Majer, Christina R.
    Jin, Lei
    Scott, Margaret Porter
    Knutson, Sarah K.
    Kuntz, Kevin W.
    Keilhack, Heike
    Smith, Jesse J.
    Moyer, Mikel P.
    Richon, Victoria M.
    Copeland, Robert A.
    Wigle, Tim J.
    [J]. FEBS LETTERS, 2012, 586 (19) : 3448 - 3451
  • [18] The Polycomb complex PRC2 and its mark in life
    Margueron, Raphael
    Reinberg, Danny
    [J]. NATURE, 2011, 469 (7330) : 343 - 349
  • [19] Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
    McCabe, Michael T.
    Graves, Alan P.
    Ganji, Gopinath
    Diaz, Elsie
    Halsey, Wendy S.
    Jiang, Yong
    Smitheman, Kimberly N.
    Ott, Heidi M.
    Pappalardi, Melissa B.
    Allen, Kimberly E.
    Chen, Stephanie B.
    Della Pietra, Anthony, III
    Dul, Edward
    Hughes, Ashley M.
    Gilbert, Seth A.
    Thrall, Sara H.
    Tummino, Peter J.
    Kruger, Ryan G.
    Brandt, Martin
    Schwartz, Benjamin
    Creasy, Caretha L.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (08) : 2989 - 2994
  • [20] Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters
    Melling, Nathaniel
    Thomsen, Erik
    Tsourlakis, Maria Christina
    Kluth, Martina
    Hube-Magg, Claudia
    Minner, Sarah
    Koop, Christina
    Graefen, Markus
    Heinzer, Hans
    Wittmer, Corinna
    Sauter, Guido
    Wilczak, Waldemar
    Huland, Hartwig
    Simon, Ronald
    Schlomm, Thorsten
    Steurer, Stefan
    Krech, Till
    [J]. CARCINOGENESIS, 2015, 36 (11) : 1333 - 1340